Literature DB >> 21502971

Treatment of refractory and recurrent Clostridium difficile infection.

Christina M Surawicz1, Jacob Alexander.   

Abstract

The incidence of Clostridium difficile infection (CDI) has increased since 2000, with greater numbers of severe cases reported, in part due to the emergence of a hypervirulent strain. Initial therapy with metronidazole is still recommended for mild to moderate CDI, but vancomycin is recommended for first-line therapy of severe CDI. Colectomy could be life-saving for some patients with severe disease that does not respond to maximal medical therapy. Recurrent CDI is a challenge to treat; no single effective therapy currently exists. Treatments include antibiotics, adjunct probiotics, fecal microbiota transplant and immune approaches. This Review discusses the various therapeutic approaches used for the treatment of refractory and recurrent CDI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21502971     DOI: 10.1038/nrgastro.2011.59

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  104 in total

Review 1.  Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis.

Authors:  Hoonmo L Koo; Diana C Koo; Daniel M Musher; Herbert L DuPont
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

2.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.

Authors:  Mary Y Hu; Kianoosh Katchar; Lorraine Kyne; Seema Maroo; Sanjeev Tummala; Valley Dreisbach; Hua Xu; Daniel A Leffler; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

3.  Clostridium difficile and inflammatory bowel disease: more questions than answers?

Authors:  Ashwin N Ananthakrishnan; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2010-08       Impact factor: 5.325

4.  Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain.

Authors:  D Seal; S P Borriello; F Barclay; A Welch; M Piper; M Bonnycastle
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

5.  Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

Authors:  Thomas J Louie; Jennifer Peppe; C Kevin Watt; David Johnson; Rasheed Mohammed; Gordon Dow; Karl Weiss; Stuart Simon; Joseph F John; Gary Garber; Scott Chasan-Taber; David M Davidson
Journal:  Clin Infect Dis       Date:  2006-07-11       Impact factor: 9.079

6.  Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients.

Authors:  Sonia S Yoon; Lawrence J Brandt
Journal:  J Clin Gastroenterol       Date:  2010-09       Impact factor: 3.062

7.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.

Authors:  Wafa N Al-Nassir; Ajay K Sethi; Michelle M Nerandzic; Greg S Bobulsky; Robin L P Jump; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2008-07-01       Impact factor: 9.079

9.  Treatment of Clostridium difficile-associated disease with teicoplanin.

Authors:  F de Lalla; G Privitera; E Rinaldi; G Ortisi; D Santoro; G Rizzardini
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

10.  Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis.

Authors:  T A Bowden; A R Mansberger; L E Lykins
Journal:  Am Surg       Date:  1981-04       Impact factor: 0.688

View more
  38 in total

Review 1.  The yin yang of bacterial polysaccharides: lessons learned from B. fragilis PSA.

Authors:  Neeraj K Surana; Dennis L Kasper
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

2.  Fidaxomicin: in Clostridium difficile infection.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

Review 3.  Stool transplants: ready for prime time?

Authors:  Jeffrey S Weissman; Walter Coyle
Journal:  Curr Gastroenterol Rep       Date:  2012-08

Review 4.  Extended duration vancomycin in recurrent Clostridium difficile infection: a systematic review.

Authors:  Madison M Murphy; Edna Patatanian; Mark A Gales
Journal:  Ther Adv Infect Dis       Date:  2018-09-12

5.  [Recurrent Clostridium difficile infection. Treatment with duodenal infusion of donor feces].

Authors:  T Seufferlein; A Kleger; S Nitschmann
Journal:  Internist (Berl)       Date:  2014-04       Impact factor: 0.743

6.  Using a Novel Lysin To Help Control Clostridium difficile Infections.

Authors:  Qiong Wang; Chad W Euler; Aurelia Delaune; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

7.  Association of relapse of Clostridium difficile disease with BI/NAP1/027.

Authors:  Jane W Marsh; Rangolee Arora; Jessica L Schlackman; Kathleen A Shutt; Scott R Curry; Lee H Harrison
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

Review 8.  Clostridium difficile infection: guideline-based diagnosis and treatment.

Authors:  Christoph Lübbert; Endres John; Lutz von Müller
Journal:  Dtsch Arztebl Int       Date:  2014-10-24       Impact factor: 5.594

9.  Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.

Authors:  Cirle A Warren; Edward J van Opstal; Mary S Riggins; Yuesheng Li; John H Moore; Glynis L Kolling; Richard L Guerrant; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

10.  Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.

Authors:  Alexa R Weingarden; Chi Chen; Aleh Bobr; Dan Yao; Yuwei Lu; Valerie M Nelson; Michael J Sadowsky; Alexander Khoruts
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-27       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.